Tocilizumab for the fifth progression of cystic childhood craniopharyngioma-a case report

Evelien de Vos-Kerkhof; Dennis R Buis; Maarten H Lequin; Carlien A Bennebroek; Eleonora Aronica; Esther Hulleman; Nitash Zwaveling-Soonawala; Hanneke M van Santen; Antoinette Y N Schouten-van Meeteren

doi:10.3389/fendo.2023.1225734

Tocilizumab for the fifth progression of cystic childhood craniopharyngioma-a case report

Evelien de Vos-Kerkhof, Dennis R Buis, Maarten H Lequin, Carlien A Bennebroek, Eleonora Aronica, Esther Hulleman, Nitash Zwaveling-Soonawala, Hanneke M van Santen, Antoinette Y N Schouten-van Meeteren

Research output: Contribution to journal › Article › Academic › peer-review

14 Downloads (Pure)

Abstract

We present the case of a 15-year-old girl, with a fifth cystic progression of an adamantinomatous craniopharyngioma after multiple surgeries and previous local radiotherapy. She had severe visual impairment, panhypopituitarism including diabetes insipidus, and several components of hypothalamic damage, including morbid obesity and severe fatigue. To prevent further late effects hampering her quality of survival, she was treated biweekly with intravenous tocilizumab, an anti-interleukin-6 agent, which stabilized the cyst for a prolonged time. Based on the biology of adamantinomatous craniopharyngioma, this immune-modulating treatment seems promising for the treatment of this cystic tumor in order to reduce surgery and delay or omit radiotherapy.

Original language	English
Article number	1225734
Journal	Frontiers in Endocrinology
Volume	14
DOIs	https://doi.org/10.3389/fendo.2023.1225734
Publication status	Published - 11 Oct 2023

Keywords

adamantinomatous craniopharyngioma
case report
cyst
hypothalamus
tocilizumab
visual impairment

Access to Document

10.3389/fendo.2023.1225734Licence: CC BY

fendo-14-1225734Final published version, 3.05 MBLicence: CC BY

Cite this

@article{664a60336dc54e10aabb288ce0e5bc84,

title = "Tocilizumab for the fifth progression of cystic childhood craniopharyngioma-a case report",

abstract = "We present the case of a 15-year-old girl, with a fifth cystic progression of an adamantinomatous craniopharyngioma after multiple surgeries and previous local radiotherapy. She had severe visual impairment, panhypopituitarism including diabetes insipidus, and several components of hypothalamic damage, including morbid obesity and severe fatigue. To prevent further late effects hampering her quality of survival, she was treated biweekly with intravenous tocilizumab, an anti-interleukin-6 agent, which stabilized the cyst for a prolonged time. Based on the biology of adamantinomatous craniopharyngioma, this immune-modulating treatment seems promising for the treatment of this cystic tumor in order to reduce surgery and delay or omit radiotherapy.",

keywords = "adamantinomatous craniopharyngioma, case report, cyst, hypothalamus, tocilizumab, visual impairment",

author = "{de Vos-Kerkhof}, Evelien and Buis, {Dennis R} and Lequin, {Maarten H} and Bennebroek, {Carlien A} and Eleonora Aronica and Esther Hulleman and Nitash Zwaveling-Soonawala and {van Santen}, {Hanneke M} and {Schouten-van Meeteren}, {Antoinette Y N}",

note = "Publisher Copyright: Copyright {\textcopyright} 2023 de Vos-Kerkhof, Buis, Lequin, Bennebroek, Aronica, Hulleman, Zwaveling-Soonawala, van Santen and Schouten-van Meeteren.",

year = "2023",

month = oct,

day = "11",

doi = "10.3389/fendo.2023.1225734",

language = "English",

volume = "14",

journal = "Frontiers in Endocrinology",

issn = "1664-2392",

publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Tocilizumab for the fifth progression of cystic childhood craniopharyngioma-a case report

AU - de Vos-Kerkhof, Evelien

AU - Buis, Dennis R

AU - Lequin, Maarten H

AU - Bennebroek, Carlien A

AU - Aronica, Eleonora

AU - Hulleman, Esther

AU - Zwaveling-Soonawala, Nitash

AU - van Santen, Hanneke M

AU - Schouten-van Meeteren, Antoinette Y N

PY - 2023/10/11

Y1 - 2023/10/11

N2 - We present the case of a 15-year-old girl, with a fifth cystic progression of an adamantinomatous craniopharyngioma after multiple surgeries and previous local radiotherapy. She had severe visual impairment, panhypopituitarism including diabetes insipidus, and several components of hypothalamic damage, including morbid obesity and severe fatigue. To prevent further late effects hampering her quality of survival, she was treated biweekly with intravenous tocilizumab, an anti-interleukin-6 agent, which stabilized the cyst for a prolonged time. Based on the biology of adamantinomatous craniopharyngioma, this immune-modulating treatment seems promising for the treatment of this cystic tumor in order to reduce surgery and delay or omit radiotherapy.

AB - We present the case of a 15-year-old girl, with a fifth cystic progression of an adamantinomatous craniopharyngioma after multiple surgeries and previous local radiotherapy. She had severe visual impairment, panhypopituitarism including diabetes insipidus, and several components of hypothalamic damage, including morbid obesity and severe fatigue. To prevent further late effects hampering her quality of survival, she was treated biweekly with intravenous tocilizumab, an anti-interleukin-6 agent, which stabilized the cyst for a prolonged time. Based on the biology of adamantinomatous craniopharyngioma, this immune-modulating treatment seems promising for the treatment of this cystic tumor in order to reduce surgery and delay or omit radiotherapy.

KW - adamantinomatous craniopharyngioma

KW - case report

KW - cyst

KW - hypothalamus

KW - tocilizumab

KW - visual impairment

UR - http://www.scopus.com/inward/record.url?scp=85174913924&partnerID=8YFLogxK

U2 - 10.3389/fendo.2023.1225734

DO - 10.3389/fendo.2023.1225734

M3 - Article

C2 - 37886643

SN - 1664-2392

VL - 14

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

M1 - 1225734

ER -

Tocilizumab for the fifth progression of cystic childhood craniopharyngioma-a case report

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this